The Detection of Cell-in-cell Structure (CICs) in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy
Launched by BEIJING SHIJITAN HOSPITAL, CAPITAL MEDICAL UNIVERSITY · Dec 6, 2022
Trial Information
Current as of January 13, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age 18-65, female;
- • Pathological biopsy confirmed invasive ductal carcinoma;
- • Karnofsky Performance Status (KPS)≥ 60, expected survival ≥4 months;
- • Locally advanced breast cancer (HER2-positive disease and TNBC, ≥cT1c or ≥cN0; HER2-negative,HR positive disease,≥cT2 or ≥cN1;Large primary tumor relative to breast size in a patient who desires breast conservation) ;
- • According to the RECIST1.1 standard, at least one measurable lesion exists;
- Exclusion Criteria:
- • Pregnant or lactating women;
- • Left ventricular ejection fraction less than 50%;
- • History of malignant tumor and concurrent occurrence of other tumors;
- • Serious medical pathology, such as congestive heart failure; unstable angina; uncontrolled high risk arrhythmias, and other serious illness or medical condition that may interfere with the study;
- • Refuse to participate in the study.
Trial Officials
Hongyan Huang, PHD
Principal Investigator
Beijing Shijitan Hospital, Capital Medical University
About Beijing Shijitan Hospital, Capital Medical University
Beijing Shijitan Hospital, affiliated with Capital Medical University, is a leading medical institution in China renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on patient-centered care and a multidisciplinary approach, the hospital is dedicated to conducting high-quality clinical trials that contribute to the understanding and treatment of various medical conditions. Leveraging its extensive network of healthcare professionals and state-of-the-art facilities, Beijing Shijitan Hospital plays a pivotal role in fostering medical advancements and improving therapeutic outcomes through rigorous scientific investigation and collaboration within the global research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials